scholarly journals Probiotic <italic>Bifidobacterium lactis</italic> V9 regulates the intestinal microbiome in patients with polycystic ovary syndrome

2018 ◽  
Vol 64 (3) ◽  
pp. 360-368
Author(s):  
Chenchen Ma ◽  
Qiannan Peng ◽  
Shuaiming Jiang ◽  
Kaining Chen ◽  
Yutuan Fang ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Intestinal Microbiome ◽  
Ovary Syndrome ◽  
Bifidobacterium Lactis

scholarly journals Probiotic Bifidobacterium lactis V9 Regulates the Secretion of Sex Hormones in Polycystic Ovary Syndrome Patients through the Gut-Brain Axis

mSystems ◽  
2019 ◽  
Vol 4 (2) ◽  
Author(s):  
Jiachao Zhang ◽  
Zhihong Sun ◽  
Shuaiming Jiang ◽  
Xiaoye Bai ◽  
Chenchen Ma ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Sex Hormones ◽  
Intestinal Microbiota ◽  
Polycystic Ovary ◽  
Intestinal Microbiome ◽  
Ovary Syndrome ◽  
Bifidobacterium Lactis ◽  
Content Type ◽  
Gut Colonization ◽  
The Impact

ABSTRACT Although a few studies have investigated the intestinal microbiota of women with polycystic ovary syndrome (PCOS), the functional and metabolic mechanisms of the microbes associated with PCOS, as well as potential microbial biomarkers, have not yet been identified. To address this gap, we designed a two-phase experiment in which we performed shotgun metagenomic sequencing and monitored the metabolic parameters, gut-brain mediators, and sex hormones of PCOS patients. In the first stage, we identified an imbalance in the intestinal microbiota of the PCOS patients, observing that Faecalibacterium, Bifidobacterium, and Blautia were significantly more abundant in the control group, whereas Parabacteroides and Clostridium were enriched in the PCOS group. In the second stage, we monitored the impact of the probiotic Bifidobacterium lactis V9 on the intestinal microbiome, gut-brain mediators, and sex hormones of 14 PCOS patients. Notably, we observed that the levels of luteinizing hormone (LH) and LH/follicle-stimulating hormone (LH/FSH) decreased significantly in 9 volunteers, whereas the levels of sex hormones and intestinal short-chain fatty acids (SCFAs) increased markedly. In contrast, the changes in the indices mentioned above were indistinct in the remaining 5 volunteers. The results of an analysis of the number of viable Bifidobacterium lactis V9 cells in the two groups were highly consistent with the clinical and SCFA results. Therefore, effective host gut colonization of the probiotic Bifidobacterium lactis V9 was crucial for its ability to function as a probiotic. Finally, we propose a potential mechanism describing how probiotics regulate the levels of sex hormones by manipulating the intestinal microbiome in PCOS patients. IMPORTANCE Polycystic ovary syndrome (PCOS) is a common metabolic disorder among women of reproductive age worldwide. Through a two-phase clinical experiment, we first revealed an imbalance in the intestinal microbiome of PCOS patients. By binning and annotating shotgun metagenomic sequences into metagenomic species (MGS), 61 MGSs were identified as potential PCOS-related microbial biomarkers. In the second stage, we monitored the impact of the probiotic Bifidobacterium lactis V9 on the intestinal microbiota, metabolic parameters, gut-brain mediators, and sex hormones of PCOS patients. Notably, we observed that the PCOS-related clinical indices and the intestinal microbiotas of the participating patients exhibited an inconsistent response to the intake of the B. lactis V9 probiotic. Therefore, effective host gut colonization of the probiotic was crucial for its ability to function as a probiotic. Finally, we propose a potential mechanism by which B. lactis V9 regulates the levels of sex hormones by manipulating the intestinal microbiome in PCOS patients.

scholarly journals Modified Guishen Pill Ameliorates Polycystic Ovary Syndrome in Rats Through Anti-inflammation and Modulating Gut Microbiota

2021 ◽  
Author(s):  
Jiayu Tian ◽  
Ling Zuo ◽  
Yanqiu Xu ◽  
Yu Xiong ◽  
Quancao Zhan ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Gut Microbiota ◽  
Ovarian Function ◽  
Polycystic Ovary ◽  
Intestinal Microbiome ◽  
High Dose ◽  
Low Grade ◽  
Group Model ◽  
Ovary Syndrome ◽  
Rdna Sequencing

Abstract Background Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder often accompanied by chronic low-grade inflammation. Western medicine often causes negative side effects, such as premature ovarian failure. Therefore, this study evaluates the efficacy of modified Guishen pill (MGP) in ameliorating letrozole-induced PCOS in rats. Methods Six-week-old specific-pathogen free (SPF) female Sprague-Dawley rats were randomly divided into a blank group (Blank), model group (Model), positive group (Diane-35, 0.2 mg/kg BW), high dose MGP group (H.MGP, 23.96 g/kg BW), medium dose MGP group (M.MGP, 11.98 g/kg BW), and low dose MGP group (L.MGP, 5.99 g/kg BW). After 4 weeks of treatment, plasma, ovaries, and fecal samples were collected from the rats for analysis. Results MGP treatment improved ovarian function by improving estrous cycle, ovarian morphology, and endocrine functions in letrozole-induced PCOS rats. MGP alleviated inflammation by reducing macrophage infiltration and inhibiting the activation of NF-κB and MAPK pathways in the ovaries of letrozole-induced PCOS rats. 16S rDNA sequencing of the intestinal microbiome indicated that MGP regulated gut microbiota structure and restored gut microbiota dysbiosis. MGP significantly increased the relative abundance of bifidobacteria at the order, family, and genus levels. Moreover, correlation analysis showed that gut microbiota were correlated with the host phenotype of letrozole-induced PCOS rats. Conclusion MGP treatment could ameliorate letrozole-induced PCOS by improving ovarian function, reducing inflammation, and regulating the gut microbiota.

The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review

2020 ◽  
pp. 1-8
Author(s):  
Daniela Menichini ◽  
Gianpiero Forte ◽  
Beatrice Orrù ◽  
Giuseppe Gullo ◽  
Vittorio Unfer ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Embryo Quality ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Endometrial Receptivity ◽  
Metabolic Disturbances ◽  
Ovary Syndrome ◽  
Beneficial Role

Abstract. Vitamin D is a secosteroid hormone that plays a pivotal role in several metabolic and reproductive pathways in humans. Increasing evidence supports the role of vitamin D deficiency in metabolic disturbances and infertility in women with polycystic ovary syndrome (PCOS). Indeed, supplementation with vitamin D seems to have a beneficial role on insulin resistance and endometrial receptivity. On the other hand, exceedingly high levels of vitamin D appear to play a detrimental role on oocytes development and embryo quality. In the current review, we summarize the available evidence about the topic, aiming to suggest the best supplementation strategy in women with PCOS or, more generally, in those with metabolic disturbances and infertility. Based on the retrieved data, vitamin D seems to have a beneficial role on IR, insulin sensitivity and endometrial receptivity, but high levels and incorrect timing of administration seem to have a detrimental role on oocytes development and embryo quality. Therefore, we encourage a low dose supplementation (400–800 IU/day) particularly in vitamin D deficient women that present metabolic disturbances like PCOS. As far as the reproductive health, we advise vitamin D supplementation in selected populations, only during specific moments of the ovarian cycle, to support the luteal phase. However, ambiguities about dosage and timing of the supplementation still emerge from the clinical studies published to date and further studies are required.

Metformin Treatment Ameliorates Liver Injury Indicating Fatty Liver Polycystic Ovary Syndrome

2015 ◽  
Vol 53 (01) ◽  
Author(s):  
S Tan ◽  
N Vollmar ◽  
S Benson ◽  
LP Bechmann ◽  
G Gerken ◽  
...  
Keyword(s):  
Liver Injury ◽  
Polycystic Ovary Syndrome ◽  
Fatty Liver ◽  
Polycystic Ovary ◽  
Metformin Treatment ◽  
Ovary Syndrome
Sign in / Sign up

Export Citation Format

Share Document